论文部分内容阅读
目的:初步研究3周小剂量多西紫杉醇单药治疗老年激素难治性晚期前列腺癌的疗效并探讨其毒副反应。方法:入选老年激素难治性晚期前列腺癌患者共18例,多西紫杉醇50 mg/m2,静脉滴入,d1;泼尼松5 mg,口服,d1~d21,2次/d,21 d为1个周期。完成4个周期后评价疗效。结果:化疗结束后,6例患者的血PSA值降至正常水平,6例PSA值下降>50%,2例PSA值变化不明显,有效率为66.67%。本组随访2~17个月,中位生存期为12.75个月,疾病进展时间为2个月,1年生存率为33.33%(6/18)。不良反应可耐受。结论:3周小剂量多西紫杉醇单药治疗老年激素难治性晚期前列腺癌有效率较高,毒副反应轻,耐受性好,并可以改善疾病相关症状,提高生存质量。
OBJECTIVE: To study the curative effect of low-dose docetaxel 3 weeks for senile hormone-refractory advanced prostate cancer and explore its toxicity. Methods: Eighteen elderly patients with hormone refractory advanced prostate cancer were enrolled in this study. Docetaxel 50 mg / m2 was given intravenously, d1, prednisone 5 mg, orally, d1 ~ d21, twice daily for 21 days 1 cycle. After completing 4 cycles to evaluate the efficacy. Results: After chemotherapy, the blood PSA levels of 6 patients dropped to normal level, the PSA value of 6 patients dropped by 50%, the PSA value of 2 patients did not change obviously, the effective rate was 66.67%. The group was followed up for 2 to 17 months, the median survival was 12.75 months, the disease progression time was 2 months, 1-year survival rate was 33.33% (6/18). Adverse reactions are tolerable. Conclusions: The three-week low-dose docetaxel single-agent treatment of advanced hormone refractory advanced prostate cancer has high efficiency, light toxicity and good tolerance, and can improve the disease-related symptoms and improve the quality of life.